Value-Based Healthcare and Regulatory Pressure

Adherence strategy is no longer optional

Healthcare systems globally are transitioning toward value-based reimbursement models. Regulators and payers increasingly demand:

• Real-world evidence
• Durable outcomes
• Demonstrated cost-effectiveness

In this environment:

Poor adherence compromises efficacy signals. Compromised data weakens reimbursement negotiations. Delayed trials postpone patient access.

Conversely. High-quality adherence strengthens:

• Clinical data robustness
• Confidence in therapeutic performance
• Market access positioning
• Competitive differentiation

Under accelerated approval pathways and outcome-based contracts, adherence performance directly influences commercial success.

Adherence strategy is no longer optional. It is foundational to long-term value creation.